课题基金 / 基金详情

Kentucky Center for Clinical and Translational Science

Kentucky Center for Clinical and Translational Science
肯塔基州临床和转化科学中心
批准号:
10681386
负责人:
Philip A Kern
金额:
$331.99万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
未结题
起止时间:
2016-08-15 至 2026-06-30

项目摘要

项目成果

Philip A Kern的其他基金

相似基金

相关文献

中文摘要
翻译
联系PD/PI:克恩、菲利普A. 项目概要-总体 肯塔基州大学(英国)临床和转化科学中心(CCTS)创建了一个 临床和转化研究的综合之家,促进科学进步和发现, 平移连续体的每一个阶段CCTS与阿巴拉契亚中部的社区合作 解决几代人之间难以解决的卫生不公平问题,部分原因是农村人口的经济困境, 社区. CCTS从根本上改变了英国和中央阿巴拉契亚通过发展 强大的学术社区研究网络和CTSA联盟内的合作。 阿帕拉契亚的健康差距因阿片类药物和药物滥用的流行而进一步扩大, 严重影响了肯塔基州东部和西弗吉尼亚州。强大的英国研究组合使英国CCTS成为 领导地方、区域和国家重点关注农村卫生不平等问题的研究工作的最佳位置。 联合王国、联合王国卫生保健和CCTS的统一使命侧重于通过参与以下活动实现卫生公平: 高度创新、协作和动态的转化研究,以满足农村卫生需求。持续关连交易 将继续教育未来的翻译劳动力,让农村社区参与翻译, 双向团队科学和工作与国家网络,以推进跨学科的研究, 临床试验通过以下具体目标:1)发展,创新和改造我们的研究环境 在我们的综合医疗保健系统内促进有影响力的科学和发现,以满足独特的健康需求。 阿巴拉契亚中部居民的需求; 2)领导机构创新,提供有影响力的临床和 涵盖生命周期的转化研究,充分参与社区并拥抱团队科学; 3) 促进一个有效的,大学范围内的临床试验组织,通过以下方式为CTSA联盟增加价值 吸引来自阿巴拉契亚中部农村地区的参与者;以及4)培养和加强一支具有以下特点的劳动力队伍: 所有转化科学学科和人群的多样性和包容性。英国CTSA中心是 在国家CTSA联盟中具有独特的地位,以促进新技术,团队科学,临床试验 在整个生命周期内开展初创和尖端的转化研究,重点是农村社区。我们 特别关注阿巴拉契亚中部社区,这是一个农村地区,有许多最高水平的 国家的健康差距。这一重点将最终提高农村人口的健康和生活质量, 美国各地的社区。 项目摘要/摘要第276页 联系PD/PI:克恩、菲利普A.
英文摘要
Contact PD/PI: Kern, Philip A. PROJECT SUMMARY – OVERALL The University of Kentucky (UK) Center for Clinical and Translational Science (CCTS) has created an integrated home for clinical and translational research which promotes scientific progress and discoveries at every phase of the translational continuum. The CCTS has partnered with communities in Central Appalachia to address multiple generations of recalcitrant health inequities related in part to the economic distress of rural communities. The CCTS has fundamentally transformed UK and Central Appalachia through the development of strong academic-community research networks and collaborations within the CTSA consortium. Appalachian health disparities are further magnified by the opioid and substance abuse epidemic, which has greatly impacted eastern Kentucky and West Virginia. The strong UK research portfolio puts the UK CCTS in an optimal position to lead local, regional and national research efforts focused on rural health inequities. The aligned missions of UK, UK HealthCare and the CCTS focus on achieving health equity by engaging in highly innovative, collaborative and dynamic translational research to address rural health needs. The CCTS will continue to educate the translational workforce of the future, engage rural communities in translational and bi-directional team science and work with the national network to advance transdisciplinary research and clinical trials through the following Specific Aims: 1) develop, innovate and transform our research environment to promote impactful science and discovery within our integrated health care system to meet the unique health needs of Central Appalachian residents; 2) lead institutional innovation in the delivery of impactful clinical and translational research that covers the lifespan, fully engages the community and embraces team science; 3) catalyze an efficient, university-wide clinical trials organization which adds value to the CTSA consortium by engaging participants from rural Central Appalachia; and 4) foster and enhance a workforce characterized by diversity and inclusivity across all translational science disciplines and populations. The UK CTSA hub is uniquely positioned in the National CTSA Consortium to foster novel technologies, team science, clinical trial start-up and cutting-edge translational research across the lifespan with a focus on rural communities. We have a particular focus on the Central Appalachian community, a rural area with many of the highest levels of health disparities in the nation. This focus will ultimately elevate the health and quality of life of rural communities throughout the United States. Project Summary/Abstract Page 276 Contact PD/PI: Kern, Philip A.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mirabegron and tadalafil effectiveness for treatment of prediabetes
  • 批准号:
    10363388
  • 项目类别:
  • 资助金额:
    $30.6万
  • 财政年份:
    2021
  • 负责人:
    Philip A Kern
  • 依托单位:
Mirabegron and tadalafil effectiveness for treatment of prediabetes
  • 批准号:
    10532229
  • 项目类别:
  • 资助金额:
    $30.6万
  • 财政年份:
    2021
  • 负责人:
    Philip A Kern
  • 依托单位:
Mechanisms for activation of beige adipose tissue in humans
  • 批准号:
    10531210
  • 项目类别:
  • 资助金额:
    $60.91万
  • 财政年份:
    2020
  • 负责人:
    Philip A Kern
  • 依托单位:
Mechanisms for Activation of Beige Adipose Tissue in Humans; Supplement
  • 批准号:
    10630687
  • 项目类别:
  • 资助金额:
    $47.25万
  • 财政年份:
    2020
  • 负责人:
    Philip A Kern
  • 依托单位:
海外基金